These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 24853733)

  • 21. Turning hepatitis C into a real virus.
    Murray CL; Rice CM
    Annu Rev Microbiol; 2011; 65():307-27. PubMed ID: 21682640
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recommendations for standardized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agents.
    Wedemeyer H; Jensen DM; Godofsky E; Mani N; Pawlotsky JM; Miller V;
    Hepatology; 2012 Dec; 56(6):2398-403. PubMed ID: 22707382
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New hepatitis C therapies: the toolbox, strategies, and challenges.
    Pawlotsky JM
    Gastroenterology; 2014 May; 146(5):1176-92. PubMed ID: 24631495
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitis C virus virology and new treatment targets.
    Meier V; Ramadori G
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):329-50. PubMed ID: 19344246
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A primer on the molecular virology of hepatitis C.
    Moradpour D; Blum HE
    Liver Int; 2004 Dec; 24(6):519-25. PubMed ID: 15566499
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cyclic phosphoramidates as prodrugs of 2'-C-methylcytidine.
    Meppen M; Pacini B; Bazzo R; Koch U; Leone JF; Koeplinger KA; Rowley M; Altamura S; Di Marco A; Fiore F; Giuliano C; Gonzalez-Paz O; Laufer R; Pucci V; Narjes F; Gardelli C
    Eur J Med Chem; 2009 Sep; 44(9):3765-70. PubMed ID: 19493593
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel hepatitis C drugs in current trials.
    Kronenberger B; Welsch C; Forestier N; Zeuzem S
    Clin Liver Dis; 2008 Aug; 12(3):529-55, viii. PubMed ID: 18625427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Coinfection with human immunodeficiency virus and hepatitis C virus: challenges and therapeutic advances. Insights from the Society of Infectious Diseases Pharmacists.
    Deming P; McNicholl IR
    Pharmacotherapy; 2011 Apr; 31(4):357-68. PubMed ID: 21449625
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interferon alpha delivery systems for the treatment of hepatitis C.
    Thitinan S; McConville JT
    Int J Pharm; 2009 Mar; 369(1-2):121-35. PubMed ID: 19103271
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progress and development of small molecule HCV antivirals.
    Ni ZJ; Wagman AS
    Curr Opin Drug Discov Devel; 2004 Jul; 7(4):446-59. PubMed ID: 15338954
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New therapeutic options for hepatitis C.
    Waters L; Nelson M
    Curr Opin Infect Dis; 2006 Dec; 19(6):615-22. PubMed ID: 17075339
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatitis C therapy--the future looks bright.
    Qureshi SA; Qureshi H; Hameed A
    Eur J Clin Microbiol Infect Dis; 2009 Dec; 28(12):1409-13. PubMed ID: 19727870
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics.
    Guedj J; Neumann AU
    J Theor Biol; 2010 Dec; 267(3):330-40. PubMed ID: 20831874
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Twenty-four hour kinetics of hepatitis C virus and antiviral effect of alpha-interferon.
    Boulestin A; Kamar N; Sandres-Sauné K; Legrand-Abravanel F; Alric L; Vinel JP; Rostaing L; Izopet J
    J Med Virol; 2006 Mar; 78(3):365-71. PubMed ID: 16419107
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current and future concepts in hepatitis C therapy.
    Pawlotsky JM
    Semin Liver Dis; 2005 Feb; 25(1):72-83. PubMed ID: 15731999
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Methods of testing potential inhibitors of hepatitis C in Huh-7.5 cell line].
    Kołakowska A; Godzik P; Madaliński K
    Med Dosw Mikrobiol; 2013; 65(4):275-83. PubMed ID: 24730216
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnosis and management of hepatitis C virus-infected children.
    Jhaveri R
    Pediatr Infect Dis J; 2011 Nov; 30(11):983-5. PubMed ID: 21997662
    [No Abstract]   [Full Text] [Related]  

  • 38. Antiviral Information Management System (AIMS): a prototype for operational innovation in drug development.
    Jadhav PR; Neal L; Florian J; Chen Y; Naeger L; Robertson S; Soon G; Birnkrant D
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):50S-55S. PubMed ID: 20881217
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improving the FDA's advisory committee process.
    Brass EP; Hiatt WR
    J Clin Pharmacol; 2012 Aug; 52(8):1277-83. PubMed ID: 21908879
    [No Abstract]   [Full Text] [Related]  

  • 40. New kinetic models for the hepatitis C virus.
    Perelson AS; Herrmann E; Micol F; Zeuzem S
    Hepatology; 2005 Oct; 42(4):749-54. PubMed ID: 16175615
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.